The definitions digital biomarker and digital phenotype are part of the everyday vocabulary of digital health. They refer to two methodological approaches, regulatory pathways, and levels of clinical inference that are gaining attention in Real-World Data (RWD) research. As digital signals move closer to informing clinical decision-making, it is essential to clearly understand what these two constructs represent.
A digital biomarker is a measurement. It is a digitally collected signal intended to reflect a biological or clinical state in a reliable and reproducible way. The term biomarker itself is inherited from traditional medicine, and the term comes with a set of expectations. Biomarkers are supposed to correlate with underlying physiology or pathology, to be validated against established standards, and to behave consistently across populations, devices, and contexts. When a digital signal is labeled a biomarker, it implicitly claims clinical relevance. It suggests that the signal can support diagnosis, monitor disease progression, predict outcomes, or inform treatment decisions. A digital biomarker is the digital analogue of a laboratory value or a blood pressure reading captured through a digital device. When heart rate variability measured through a smartwatch is used as a proxy for autonomic nervous system function, or when a smartphone’s accelerometer quantifies the frequency and amplitude of a Parkinson’s tremor, the intent is to isolate a specific, measurable parameter and link it to a known biological construct.
In contrast, a digital phenotype is not a single measurement but the representation of an individual’s health status, behaviors, and disease characteristics as inferred from data generated through digital technologies during everyday life and routine care. A digital phenotype is built from digital traces such as electronic health records (EHRs), wearable sensors, smartphones, medical devices, and other RWD sources. It reflects not only biological signals but also patterns of behavior, care pathways, environmental exposure, and interactions with healthcare systems. The emphasis shifts from precision around a single signal to coherence across many signals. A digital phenotype might combine mobility data derived from GPS, sleep architecture captured by a wearable, and engagement patterns with a patient-reported outcome app to infer functional status or disease stability. Its value lies in revealing structure and variability in lived experience rather than in establishing clinical ground truth.
A fundamental distinction between biomarkers and phenotypes relates to their dependence on contextual information. Digital biomarkers are often designed to be as context-independent as possible. The goal is to extract a pure physiological signal and minimize the influence of external factors. A tremor measurement should reflect neurological dysfunction, not whether the patient happens to be on a bus.
Digital phenotypes, on the other hand, are highly context-dependent. A reduction in physical activity is not treated as a standalone number but as a behavioral signal that gains meaning only when interpreted alongside other data. Within a phenotyping framework, a drop in step count may be interpreted very differently depending on whether it coincides with adverse weather conditions, a recent prescription refill, a hospitalization, or a self-reported increase in fatigue. This ability to synthesize heterogeneous data points into a coherent narrative is what makes digital phenotyping particularly powerful for real-world evidence (RWE), as it allows researchers to reconstruct aspects of the patient’s lived experience that were previously invisible.
These conceptual differences translate into very different technical and methodological challenges. For digital biomarkers, technical precision is key. The dominant concern is signal fidelity and signal-to-noise ratio. Developers must demonstrate that what is being measured truly corresponds to the intended biological phenomenon. In a Parkinson’s disease application, for example, it is not enough to detect movement; one must show that the detected signal reflects pathological tremor rather than voluntary motion or environmental vibration. Validation is therefore central. A digital biomarker must prove that it measures what it claims to measure, that it does so reliably across devices and settings, and that it adds value beyond existing clinical assessments. The bar is intentionally high, because the consequences of error can be serious, ranging from delayed diagnosis to inappropriate clinical decisions.
Digital phenotypes face a different kind of risk, one that is more interpretative than technical. Because a phenotype is an inferred state rather than a direct measurement, it is intrinsically vulnerable to confounding. A pattern that appears to indicate worsening depression, inferred from reduced social communication and altered sleep patterns, may instead reflect grief, a major life transition, or a change in work schedule. The challenge of digital phenotyping is therefore not only collecting large volumes of data, but applying rigorous clinical reasoning and methodological discipline to ensure that the inferred construct aligns with clinical reality.
This difference in logic also explains why digital phenotypes are often discovered rather than predefined. Patterns emerge from data, correlations are observed, and hypotheses are generated. Changes in typing speed may correlate with mood fluctuations, irregular sleep–wake cycles may align with cognitive decline, and subtle shifts in movement patterns may precede clinical events. These signals can be extremely valuable for research, early detection, and population-level insights. However, correlation does not equal measurement. A phenotype can be informative without being definitive, and problems arise when exploratory signals are prematurely presented as validated biomarkers.
In practice, digital phenotypes are easier to generate than digital biomarkers. They require less upfront validation and can produce compelling narratives quickly. Large datasets often reveal patterns that feel intuitively meaningful, and there is a natural temptation to frame those patterns in clinical language.
Interestingly, many digital biomarkers may begin their life as phenotypes, emerging from exploratory analyses that later inspire focused validation efforts. Phenotyping can be seen as the discovery phase, while biomarker development represents maturation. A digital phenotype can be valuable even if it never becomes a biomarker, while a digital biomarker, once claimed, carries obligations that need to be satisfied.
Regulators have increasingly accepted digital biomarkers as surrogate or supportive endpoints, provided the validation package is rigorous and transparent. Digital phenotypes, by contrast, are viewed with healthy skepticism because of their complexity and their dependence on data that inevitably inherit the biases, gaps, and structural inequities of the systems that generate them. A phenotype built from EHR and wearable data reflects how people access care, how clinicians document, and how comfortable patients are with digital tools. For those working with RWE, due diligence means looking beyond the phenotype itself and examining where the data comes from and how it was put together.
Looking ahead, especially in complex therapeutic areas such as oncology, neurology, and rare diseases, the synergy between digital biomarkers and digital phenotypes is likely to become increasingly important. The challenge is no longer simply to collect more data, but to understand the hierarchy within that data, moving from raw signals, to contextualized patterns, to validated markers, and ultimately to a richer understanding of human health in the digital age.
The distinction between digital biomarkers and digital phenotypes forces a simple but uncomfortable question: are we describing what we observe, or claiming what we measure?
